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Objectives. This study was designed to examine the possibility 
that spontaneous regression in stenosis everity occurs over time 
in patients with restenosis after percutaneous transluminal coro- 
nary angioplasty. 
Background. The underlying mechanisms of restenosis are 
intimal hyperplasia nd smooth muscle cell proliferation in 
response to vascular injury. We hypothesized that the initial 
hyperplastic response is followed by dynamic remodeling and 
eventual spontaneous regression, leading to stabilization or a 
reduction in stenosis severity. 
Methods. A total of 136 patients participated in a trial to 
evaluate the efficacy of fish oil versus placebo in preventing 
restenosis after angioplasty. One hundred thirteen patients com- 
pleted this study with angiographic follow-up, of whom 56 had 
restenosis. Of these, 19 were asymptomatic and did not undergo 
repeat revascularization; 15 consented in a separate study to 
undergo repeat angiography, which was performed 6 to 25 months 
later to assess the possibility of regression. 
Results. There was a significant mean (-+SD) decrease in lesion 
severity from 66.9 -+ 8.7% to 47.5 -+ 9.0% (p < 0.0001) and a 
significant mean increase in minimal lumen diameter from 0.91 +- 
0.31 mm to 1.44 -+ 0.35 mm (p < 0.0001). No patient showed 
progression of stenosis, but regression of restenosis, defined as a 
decrease in minimal lumen diameter >0.2 ram, was noted in 12 of 
the patients. 
Conclusions. Although all 15 study patients were asymptomatic, 
similar changes may occur in symptomatic patients. A trial of 
medical therapy may be appropriate in asymptomatic or mildly 
symptomatic patients before further interventions. This strategy 
would avoid unnecessary invasive procedures, prevent a "resten- 
osis cycle" and result in significant cost savings. 
(J Am Coil Cardiol 1995;26:696-702) 
Despite dramatic improvements in equipment design and the 
primary, success rate of coronary angioplasty, the long-term 
etficacy of the procedure remains limited because of the 
perplexing problem of restenosis (1,2). Although significant 
advances have been made in understanding various mecha- 
nisms of the restenosis process (3-6}, attempts to lower the 
incidence of restenosis by using aggressive pharmacotherapy 
and newer devices have met with very limited success. Re- 
stenosis remains the major drawback of all transcatheter 
interventions, resulting in repeat procedures, increased mor- 
bidity and rising costs (7). 
In recent published reports the process of restenosis is 
regarded as a unique vascular expression of the systemic 
wound-healing response (6) and is initiated by injury to the 
vessel wall, resulting in the release of thrombogenic, vasoactive 
and mitogenic factors (7). The major events to follow are 
platelet aggregation, thrombus formation, inflammatory cell 
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infiltration, smooth muscle cell migration and proliferation 
with proteoglycan deposition. Passive contraction of the di- 
lated segments causing elastic recoil may also be evident in the 
early hours after angioplasty (8). This process results in a 
variable degree of lumen renarrowing in almost all patients 
after angioplasty (9). According to the definitions used in 
various angiographic trials, 25% to 55% of these segments are 
identified as restenotic (10). 
Despite a plethora of data on 6-month angiography, the 
standard measure of restenosis, little is known about the 
natural history of restenosis beyond this time frame. We 
propose that in the absence of further vascular injury, the 
initial hyperplastic response is followed by a dynamic remod- 
eling of the vessel wall, leading to significant spontaneous 
angiographic regression of restenosis. Two distinct mecha- 
nisms may account for the increase in the lumen diameter. 
Restenosis regarded in recent reports (6,11,12) as a unique 
vascular expression of systemic wound healing. Similar to the 
contraction of scar tissue during the final phase of systemic 
wound healing, the hyperplastic neointimal mass at the resten- 
osis site may shrink, and this neointimal thinning in the chronic 
phase would result in spontaneous regression of restenosis. 
Another independent mechanism playing a role during this 
chronic phase is arterial dilation as a compensatory response to 
intimal hyperplasia, as demonstrated by intravascular ultra- 
sound in a subgroup of patients after transcatheter interven- 
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tions (13). These factors would result in significant spontane- 
ous angiographic regression of restenosis. 
Methods  
Patients. Between October 6, 1990 and May 7, 1993, 136 
patients were enrolled at the Kaiser Permanente Medical 
Center in Los Angeles in the multicenter double-blind placebo- 
controlled Fish Oil Restenosis Trial (FORT) (14) to evaluate 
the etfieacy of fish oil in preventing restenosis after angioplasty. 
Of these, 113 completed the study and underwent exit angiog- 
raptly to evaluate possible restenosis. By the study definition of 
restenosis-->-30% increase in narrowing or a loss of 50% of 
the gain achieved at the time of successful angioplasty, and a 
stenosis >-50% on exit angiography (15)--56 patients were 
found to have restenosis during the 6 months of follow-up. 
Thirty-seven of the patients with restenosis had recurrent 
ischemic symptoms and were treated by repeat revasculariza- 
tion. Nineteen patients with restenosis were asymptomatic and 
did not undergo further intervention. Fifteen of these patients 
prospectively consented to participate in a separate angio- 
graphic study designed to assess the late natural history of 
restenosis and the hypothesis of spontaneous regression. The 
study protocol was reviewed and approved by the institutional 
review board. The time interval between exit from the parent 
trial and repeat late angiography in this study was 6 to 25 
months (mean [+_SD] 13 +_ 6 months). All study patients were 
evaluated and followed up clinically. 
Angiography. All angiographic procedures were per- 
formed by experienced operators under optimally standardized 
conditions to minimize measurement variability using the same 
procedure room, catheter equipment, matched angiographic 
projections and the administration of intracoronary nitroglyc- 
erin before each angiographic study. 
Quantitative coronary angiography was performed by the 
core angiographic laboratory used in the FORT study (Baylor 
College of Medicine) using the computer-based Cardiovascu- 
lar Angiographic Analysis System (CAAS) (16,17). This sys- 
tem, which utilizes automated edge detection and corrects for 
pincushion distortion, has been extensively validated (16,17). 
The intraobserver variability using this system is 0.2 mm (18). 
The values for the reference diameter (normal-appearing 
segment proximal to the stenotic segment), minimal lumen 
diameter (MLD) and percent diameter stenosis ([1 - MLD/ 
Reference diameter] x 100) were measured before and imme- 
diately after angioplasty and at 6-month and late follow-up 
angiography. 
Definition of regression and progression. Regression was 
defined as an increase in minimal umen diameter ->0.2 mm on 
late angiography compared with that at 6-month angiography. 
Conversely, progression was defined as a decrease -<0.2 mm in 
minimal lumen diameter between these two time frames. A 
lesion was considered stabilized if it showed neither egression 
nor progression. 
Statistical analysis. Results are expressed as mean value _+ 
SD. Comparative analysis between 6-month and late follow-up 
Table 1. Demographic and Clinical Characteristics of 15 
Study Patients 
Mean age (yr) 63.7 
Range 48 -75 
Male/female 11/4 
Cardiac risk factors 
Hypertension 9 
Diabetes mellitus 2 
Smoking 5 
Hypercholesterotemia 9 
Family history 5 
Angina None 
Fish oil/placebo in parent rial 9/6 
Vessel undergoing angioplasty 
LAD 5 
Cx 5 
RCA 5 
Data presented are number of patients, unless otherwise indicated. Cx 
(LAD, RCA) = circumflex (left anterior descending, right) coronary artery. 
angiography was based on the paired t test. The relation of 
changes in stenosis everity and minimal umen diameter with 
potential risk factors, including those in Table 1, length of 
follow-up time and reference diameter were examined using 
analysis of covariance methods. A probability value <0.05 was 
regarded as significant. 
Results  
Fifteen of 19 patients with asymptomatic restenosis from 
the parent trial consented to repeat angiography at least 6 
months after exiting from the study (mean 13 -+ 6 months, 
range 6 to 25). Four patients declined repeat angiography. The 
demographics and clinical characteristics of the patients are 
presented in Table 1. 
Angiography. The quantitative coronary angiographic 
measurements of minimal lumen diameter and percent diam- 
eter stenosis and the interval changes in these measurements 
are shown in Table 2. All patients manifested an improvement 
in minimal lumen diameter and a reduction in percent diam- 
eter stenosis from 6-month to late follow-up angiography. In 12 
patients the magnitude of improvement exceeded the intraob- 
server variability of the angiographic technique (0.2 ram) and 
therefore constituted significant regression of the stenosis. No 
patient exhibited progression of restenosis. Overall the mean 
(_+SD) percent diameter stenosis for the 15 patients at exit 
from the parent study was 66.9 _+ 8.7%. The final follow-up 
percent stenosis was 47.5 _+ 9.0%. This result represents a 
significant (p < 0.0001) absolute mean decrease of 19.3 _ 
12.5%. The mean minimal lumen diameter at exit from the 
parent study was 0.91 _+ 0.31 ram. The final follow-up minimal 
lumen diameter was 1.44 +_ 0.35 ram. The absolute mean 
increase in minimal lumen diameter was 0.53 _+ 0.36 mm, 
which represents a significant mean increase in lumen diame- 
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Table 2. Quantitative Corona~, Angiographic Measurements at6 
Months After Angioplasty and at Late Follow-Up, Demonstrating 
Interval Change Representing Degree of Regression i  Each Patient 
Minimal Lumen Diameter (mm) Percent Diameter Stenosis 
Pt Interval Interval 
No. 6 mo Late Change 6 mo Late Change 
l 1.59 170 0. I1 53 50 - 3 
2 0.71 1.47 1i.76 73 43 30 
3 1.36 1.64 ii.28 53 44 9 
4 0.83 1.73 {I.911 70 37 33 
5 1.21 1.64 II.43 55 39 16 
6 0.99 1.67 11.68 67 45 22 
7 0.57 (I.92 (I,35 74 58 16 
8 1. I t) 1.60 0.41 56 42 14 
9 0.69 1.99 1.30 77 30 41 
10 0.58 1.66 l.OS 79 40 39 
1 l (I.86 I.(19 (I.23 t~6 56 10 
12 0.54 1.26 0.72 76 45 31 
13 1.08 1.43 0.35 (~2 49 13 
14 0.59 0.70 O. 1 I 7ll 64 0 
15 0.86 l.Ii5 0.19 72 65 7 
Pt = patient. 
ter (p < 0.0001). The mean values of the reference diameter 
and diameter before and after angioplasty and at 6-month and 
late angiography are shown in Figure 1. The reference diam- 
eter remained remarkably constant at each time frame. The 
individual measurements of minimal lumen diameter and 
percent diameter stenosis are graphically displayed in Figures 
2 and 3, respectively. The angiographic sequence in one patient 
(Patient 4) is shown in Figure 4. 
There were no adverse clinical events during the follow-up 
period. There was no relation of regression to the particular 
vessel in which the angioplasty was performed. The results of 
the covariate analysis are presented in Table 3. The model 
includes all potential predictors that measurably explained 
(partial correlation) the variation in the regression in stenosis 
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Figure 2. Serial changes in individual measurements of absolute 
diameter of the stenotic segments for each patient (hatched lines) and 
mean absolute diameter of the stenotic segments for the study group 
(solid line) before (Pre PTCA) and immediately after angioplasty 
(Post PTCA) and at 6-month and late (Final) follow-up angiography. 
severity. None of the factors reached statistical significance. Of 
special interest was the time span between exit from the parent 
study and the performance of final angiography (days), which 
was not related to the regression in stenosis severity (p = 
0.7443). The multiple correlation coefficient that measures the 
variation explained by all the factors considered was also not 
significant (R = 0.679, p = 0.844). 
Discuss ion  
Previous studies. Restenosis remains an enigmatic prob- 
lem, occurring in 25% to 55% of patients (9,10,18-22) despite 
application of newer interventional techniques and use of a 
wide variety of pharmacologic agents (14,23-30). This variabil- 
ity in restenosis rates appears to be related to the criteria and 
angiographic techniques used in each study (18,20,21,31-34). 
Angiographic studies have shown that almost all lesions dete- 
Figure 1, Serial changes in mean absolute diameter of the reference 
segments (hatched line) and stenotic segments ( olid line) before (Pre 
PTCA) and immediately after angioplasty (Post PTCA) and at 
6-month and late (Final) follow-up angiography. 
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Figure 3. Serial changes in percent diameter stenosis for each patient 
(hatched lines) and mean percent diameter stenosis for the study 
group (solid line) before (Pre PTCA) and immediately after angio- 
plasty (Post PTCA) and at 6-month and late (Final) follow-up angiog- 
raphy. 
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riorate to a certain degree by 120 days after angioplasty (9) and 
that restenosis peaks at 4 months, with little further loss of 
lumen diameter up to 1 year after angioplasty (9,19). A 
reduction in overall lesion severity at 3 years compared with 
that 6 months after angioplasty in all patients undergoing the 
procedure has been shown (35); however, the natural history of 
restenotic lesions has not been described. 
Present study. The present study describes a previously 
unrecognized phenomenon of spontaneous regression of re- 
stenotic lesions. All 15 patients showed improvement in the 
measured variables of minimal lumen diameter and percent 
stenosis, and 12 manifested istinct regression as defined. 
Figure 4. Right anterior oblique projection of the left anterior de- 
scending coronary artery in Patient 4. A, Preangioplasty angiogram 
showing a minimal umen diameter of 0.33 mm and 88% diameter 
stenosis. B, Angiogram immediately after angioplasty showing a min- 
imal lumen diameter of 1.88 mm and 31% diameter stenosis. C, 
Six-month follow-up angiogram demonstrating restenosis, with a min- 
imal lumen diameter of 0.83 mm and 70% diameter stenosis. D, Final 
follow-up angiogram showing regression of restenosis, with a minimal 
lumen diameter of 1.73 mm and 37% diameter stenosis. 
Table 3. Potential Predictors of Regression in Stenosis Severity 
(covariate analysis) 
P 
Factor Coefficient SE Value 
Constant 0.9939 1.5501 0.5497 
Days -0.0004 0.0012 0.7443 
Age 0.0032 0.0234 0.8952 
Male gender 0.1158 0.3371 0.7452 
Hypertension -0.0346 0.3110 0.9156 
Diabetes 0.0762 0.6548 0.9118 
Smoking 0.4663 0.4944 0.3889 
Cholesterol -0.2833 0.6501 0.6811 
Family history 0.4330 0.5532 0.4693 
Treatment (fish oil) -0.1804 0.5405 0.7522 
There was a relative increase in minimal lumen diameter of 
58% (0.91 to 1.44 ram, p < 0.0001) (Fig. 2) and relative 
reduction in lesion severity of 28.9% (66.9% to 47.5%, p < 
0.0001) (Fig. 3). 
Pathogenesis of restenosis. The pathogenesis of restenosis 
is not completely understood. The process is multifactorial, 
700 MEHTA ET AL. JACC Vol. 26, No. 3 
REGRESSION OF RESTENOSIS September 1995:696-702 
involving mural thrombus formation (18,36-40) and elastic 
recoil (41-45) early after the procedure. Later events are 
believed to be a vascular expression of similar events een in 
wound healing (6,46). Balloon angioplasty leads to intimal 
denuding and medial stretch injury (47-51), which is followed 
by platelet aggregation at the site (6,52). The distorted endo- 
thelium and platelets release vasoactive substances and growth 
factors (53-57). In response to these stimuli, smooth muscle 
cells migrate from the media and surrounding tissue to the 
intima and proliferate, with formation of a connective tissue 
matrix (56,58-62). This process occurs to a certain extent in all 
patients (9) and leads to restenosis n some. 
Mechanism of regression. The mechanism of regression 
seen in our patients remains peculative. Smooth muscle cells 
have two phenotypes (56,58,63,64). The contractile phenotype 
predominates in the normal vessel wall and is unresponsive to
growth factors. The synthetic phenotype is closely related to the 
fibroblast. This phenotype is responsive to growth factors and 
is secretory, producing extracellular matrix, proteoglycan and 
collagen. After arterial injury, the synthetic phenotype smooth 
muscle cells migrate and proliferate in response to growth 
factors. By 2 weeks the synthetic smooth muscle cells are 
replaced by the contractile phenotype (6,64,65). lntimal hyper- 
plasia reaches a peak at 4 to 12 weeks (66-69). As prolifera- 
tion of smooth muscle cells diminishes, proteoglycan synthesis 
continues, and the relative volume of the intimal hyperplasia 
mass occupied by smooth muscle cells decreases (6,67). By 180 
days the relative percent of contractile phenotype smooth 
muscle cells has returned to baseline levels (64). At this point 
there is a decreasing stimulus for proliferation, and regression 
may occur through a process similar to the final phase of 
wound healing. The underlying mechanism during this period 
in wound healing is contraction of the extraceilular matrix and 
collagen fibers (11). A compensatory arterial dilation in re- 
sponse to restenosis has also been demonstrated by intravas- 
cular ultrasound (13). The exact relation of this observation to 
the regression observed in the present study is unclear, and the 
mechanism of this phenomenon needs to be studied. 
Clinical implications. Although angiographic restenosis 
occurs frequently, 24% to 48% (20,70) of patients remain 
asymptomatic and have an excellent prognosis (70). All 15 
patients in the present study remained asymptomatic and 
without adverse cardiac events. This result, coupled with the 
observed spontaneous regression, suggests that searching for 
ischemia in asymptomatic patients by elaborate, xpensive and 
invasive tests may not be necessary. Because the incidence of 
acute myocardial infarction in patients with restenosis i low 
(71,72), repeat interventions could be reserved for more 
symptomatic patients. It is conceivable that mildly symptom- 
atic patients treated medically may become asymptomatic 
through this process of spontaneous regression. This avoids the 
cycle of repeat interventions and their consequences. A pro- 
spective trial in mildly symptomatic patients may be needed to 
assess the full clinical implications of the present study. 
Conclusions. Significant spontaneous regression or stabili- 
zation of restenotic lesions was noted in all 15 patients. There 
were no adverse clinical events in this group. Although no 
predictors of spontaneous regression of restenosis were found, 
this result may be related to the small number of patients in the 
present study. Similar to the process of restenosis, a variable 
degree of regression appears to involve the entire study 
population and therefore may be expected in patients with 
symptomatic restenosis as well. A trial of medical therapy in 
mildly symptomatic patients with restenosis may be appropri- 
ate before further interventions. This strategy will lead to 
avoidance of unnecessary interventions and prevent he "re- 
stenosis cycle," resulting in significant cost savings. 
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